Vasopharm GmbH

https://www.vasopharm.com

vasopharm is focused on the development of small molecule therapeutics which modulate the bioavailability of biological NO, by addressing the entire NO/cGMP signal cascade and its functional counterpart NOX. vasopharm’s drug candidate VAS203 represents a completely new class of NOS modulators targeting cerebral vessels and cerebral tissue. For VAS203, vasopharm received orphan drug designation for the treatment of moderate and severe TBI in Europe. *

	Start	1998-07-01 splitoff
	Predecessor	University of Würzburg
	Industry	cardiovascular drug
	Industry 2	ronopterin (VAS203)
	Person	Wandersee, Christian (Vasopharm GmbH 201306 Managing Director)

	Region	Würzburg
	Country	Germany
	Street	15 Friedrich-Bergius-Ring
	City	97076 Würzburg
	Tel	+49-931-359099-0
		Address record changed: 2022-10-02

Basic data	Employees	n. a.

		* Document for »About Section«:

		Record changed: 2023-12-30

Picture Berlin Partner Voices Robinson Data for Precision Medicine 650x200px

More documents for Vasopharm GmbH

[1] Vasopharm GmbH. (7/11/19). "Press Release: Vasopharm Closes € 9.5 Million Financing Round"....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]